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1  | INTRODUC TION
Islet transplantation (ITx) is an effective treatment for patients with 
Type 1 diabetes with frequent, severe hypoglycemia associated 
with impaired awareness of hypoglycemia even in the absence of 
completely normal glucose tolerance or insulin independence.1-5 
Intrahepatic ITx can achieve short- term insulin independence in al-
most all cases. Factors promoting ITx success include islet number1,6 
and purity, 7 but long- term insulin independence is difficult to main-
tain.2,8,9 Attrition in graft function is well recognized although poorly 
understood. Mechanisms for the diminished graft function observed 
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Abstract
Following islet transplantation, mixed meal tolerance tests (MMTs) are routinely utilized 
to assess graft function, but how the 90- minute MMTT glucose value relates to a 
120-	minute	glucose	concentration	of	≥11.1	mmol/L	used	to	diagnose	diabetes	follow-
ing a standardized 75 g- OGTT, is not known. We examined this relationship further. 
Thirteen subjects with Type 1 diabetes and stable transplant grafts, not on exogenous 
insulin with HbA1c < 7% (53 mmol/mol), were studied on 17 occasions with paired 
OGTTs and MMTTs. Receiver operating characteristic (ROC) curves were constructed 
to derive the 90- minute MMTT glucose threshold associated with a 120- minute glucose 
concentration following a 75 g- OGTT (OGTT120)	≥11.1	mmol/L	and	their	diagnostic	ac-
curacy. Studies with OGTT120	≥11.1	mmol/L	(n	=	5)	had	diminished	C-	peptide:	glucose,	
greater integrated glucose and diminished insulin: glucose area under the curve (AUC) 
ratios (0- 120 minutes) and disposition indices; all P < .05, contrasting with MMTTs 
where no difference in the 90- minute glucose concentrations, C- peptide:glucose, inte-
grated glucose, C- peptide and C- peptide: glucose AUCs (0- 90 minutes) was seen; all 
P	>	.05.	A	90-	minute	MMTT	glucose	concentration	≥8.0	mmol/L	demonstrated	a	sensi-
tivity	and	specificity	of	≥80%	for	the	diagnosis	of	OGTT120	≥11.1	mmol/L;	area	under	
ROC	curve	(mean	±	SEM)	73	±	13%.	A	90-	minute	MMTT	glucose	≥8.0	mmol/L,	identi-
fies islet transplant recipients who may require closer monitoring for graft dysfunction.
K E Y W O R D S
islet transplantation, mixed meal tolerance tests, oral glucose tolerance tests, receiver 
operating characteristic curves
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution	License,	which	permits	use,	distribution	and	reproduction	in	any	medium,	
provided the original work is properly cited.
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with time may include autoimmune and alloimmune processes and 
an intrahepatic environment that is toxic as a consequence of expo-
sure of islets to high concentrations of immunosuppressive drugs; 
the relatively low oxygen concentration in the liver may also play a 
role.10 Monitoring of graft function11 is therefore of importance in 
the follow up care of patients to identify individuals who may require 
metabolic or immunologic support to prevent further graft loss.
Measures of beta- cell function may be made directly from circu-
lating C- peptide concentrations12 after stimulation with arginine13 
and glucagon tests14 or indirectly using surrogate measures, for exam-
ple using continuous glucose monitoring systems.15,16 Recently, it has 
been demonstrated that a measure of ITx engraftment may be derived 
from a fasting C- peptide measurement,11 but islet transplantation pro-
grammes across the world have long recognized stimulated C- peptide 
measurements as an appropriate primary outcome measure.2,4,17,18 
The most used method for stimulating C- peptide response in islet 
transplant recipients in clinical settings is the mixed meal tolerance 
test (MMTT) as it is highly reproducible and represents a robust but 
physiological stimulus for C- peptide secretion with a lower risk of hy-
perglycemia, because a smaller load of glucose is used, as compared 
to an OGTT.19 In the MMTT, a liquid meal is ingested in the fasting 
state with timed measurements of C- peptide and other metabolites 
post- prandially. In islet transplantation programmes, the post- prandial 
C- peptide concentration at 90- minutes is taken to reflect the peak 
stimulated circulating C- peptide concentration and is interpreted in 
the context of the glucose concentration at this time point.20
The purpose of metabolic testing with MMTT after islet trans-
plantation is to assess graft function rather than to define glucose 
intolerance or recurrence of diabetes. This is in contrast to the use of 
OGTT to diagnose degrees of glucose intolerance including impaired 
fasting glucose, impaired glucose tolerance and post- transplant 
diabetes in other transplant settings,21 using the same thresholds 
defined	 by	 the	 WHO	 (plasma	 glucose	 ≥11.1	mmol/L	 (200	mg/dL)	
2 hours after a 75 g oral glucose load) to diagnose diabetes in the 
general population22 (See Appendix S1—WHO Classification of 
Glucose Intolerance). The presence of diabetes nevertheless indi-
cates inadequate insulin secretion (in absolute or relative terms) to 
maintain euglycaemia.23-26 Thus the excursions in glucose and C- 
peptide after either a MMTT and OGTT reflect beta- cell capacity.
As OGTTs are not performed routinely and no previous studies 
have explored the responses to both MMTT and OGTT in islet trans-
plant recipients, we sought to compare the metabolic responses 
to MMTT and OGTT in a small cohort of insulin- independent islet 
transplant recipients who had undergone both tests. This also af-
forded the opportunity to determine the glucose thresholds at 
90- minutes following a MMTT that corresponded to the threshold 
for diagnosis of diabetes after a 75 g- OGTT.
2  | RESE ARCH DESIGN AND METHODS
In the original Edmonton Protocol, beginning in 1999, MMTTs 
were performed routinely before and at 3, 6, 12, and 18 months, 
and OGTTs performed at 6 and 12 months, post- transplant.18 
Subsequently, OGTTs were performed infrequently as patients dis-
liked exposure to large glucose loads and generally only in insulin- 
independent subjects. We analyzed data from metabolic studies 
performed between 1999 and 2003 in subjects who had received 
their first islet infusion before 2002. The induction and mainte-
nance immunosuppression received by subjects reflects the original 
Edmonton Protocol (daclizumab at induction and maintenance with 
sirolimus	(8-	10	ng/mL)	and	tacrolimus	[4-	6	ng/mL]).
2.1 | Participants
Data from thirteen insulin- independent islet transplant recipients 
from Edmonton, with stable graft function, defined as capillary 
blood	glucose	readings	<10	mmol/L	(tested	4	times	per	day	over	the	
previous 1 month), without exogenous insulin therapy or oral hypo-
glycemic agents with HbA1c <7% (53 mmol/mol) and normal renal 
function	(eGFR>60	mL/min)	and	who	had	undergone	paired	MMTTs	
and OGTTs are presented.
2.2 | Metabolic studies
Three days before all studies, participants were asked to consume 
250 g carbohydrates per day and abstain from alcohol or strenu-
ous exercise, after which participants were studied in the Clinical 
Research Facility after an overnight fast of 8- 10 hours. The MMTT 
and OGTT tests took place on separate study days. The order of the 
paired tests were randomised.
Height was recorded to the nearest 0.5 cm, weight to the 
nearest 0.1 kg (SECA 761 scales) and information regarding med-
ications over the previous 1 week recorded. All participants had 
a 44- mm, 20- gauge cannula inserted in the left forearm for ve-
nous blood sampling. Participants acclimatized for 30 minutes 
prior to the ingestion of glucose or the mixed meal as previously 
described.27 The participant remained seated for the duration of 
the test.
2.2.1 | Standardized MMTT
Sampling for glucose and C- peptide was performed at baseline 
and	90-	minutes	after	drinking	Ensure	HP	(6	mL/kg	body	weight	to	
a maximum of 360 mls consumed within 5 minutes, providing 1.1 
Calories/mL;	23%	fat,	55%	carbohydrate	and	22%	protein).11,27
2.2.2 | 75 g OGTT
Sampling for glucose, C- peptide and insulin were performed at base-
line and then following ingestion of 75 g glucose at time 30, 60, 90 
and 120 minutes.
All samples were centrifuged at 704 g for 15 minutes at 4°C, sep-
arated	and	the	plasma	frozen	at	−70°C	until	analysis.
Biochemical assays were measured in duplicate and concen-
trations determined by the glucose oxidation method. C- peptide 
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and insulin concentrations were measured using commercial kits 
(Roche Elecsys, Roche Diagnostics, Indianapolis, IN; and Pharmacia, 
Uppsala Sweden respectively) with lower limit of assay sensitivities 
of	0.02	nmol/L	and	0.35	nmol/L	respectively.27
2.3 | Ethical approval
Participants provided written informed consent and the study was 
approved by University of Alberta Health Research Ethics Board, 
and conducted in accordance with the principles endorsed by the 
Declaration of Helsinki and the Declaration of Istanbul.
2.4 | Data analysis
Measures of insulin resistance were derived from the HOMA- IR28 
and the Matsuda index29 as measures of hepatic insulin resistance 
and whole body insulin sensitivity respectively.30 The insulinogenic 
index was derived as a surrogate measure of insulin secretion31,32 
and the disposition index (DI) derived from the product of the 
Matsuda index and the insulinogenic index30; a DI <1 is evidence 
of diminished insulin secretion in relation to the insulin sensitivity. 
Beta27 and BETA- 2 scores 11 were calculated as composite measures 
of graft function (See Appendix S1 - Formulae of Scores).
2.5 | Statistical analyses
Statistical analyses were performed using STATA version 15 (Stata 
Corporation, TX, USA). Descriptive statistics are expressed as 
mean ± SEM and median(IQR) as appropriate. Data sets were com-
pared using unpaired t tests, Mann- Whitney U tests and ANOVA 
analyses with post hoc testing. Comparisons between intra- 
individual OGTTs and MMTTs were compared by paired t tests or 
Wilcoxon signed rank tests. The association between stimulated 
glucose values during the OGTT and MMTT were tested with 
Pearson correlation testing. The data sets were further compared 
without including the repeated measurements in the 4 participants. 
Area under the ROC (AUROC) curves were calculated with the 
90- minute MMTT glucose concentrations according to OGTT120 
≥11.1	mmol/L	(200	mg/dL),	the	glycaemic	threshold	consistent	with	
a diagnosis of diabetes (WHO criteria), to determine the accuracy 
of the test. The 90- minute MMTT glycaemic threshold correspond-
ing with an OGTT120	≥11.1	mmol/L	with	maximum	sensitivity	and	
Personal data All OGTT
120
 <11.1 OGTT
120
 ≥11.1 P
Number of subjects 13 9 4 - 
Number of paired 
OGTT and MMTT
17 12 5 - 
Insulin- independent 
(%)
100 100 100 - 
Male: female 9:4 6:3 3:1 .99
Age (years) 45.0 ± 2.6 42.6 ± 2.8 50.5 ± 4.8 .16
BMI (kg/m2) 22.1 ± 0.70 22.3 ± 0.94 21.7 ± 0.98 .73
Pre- transplant dose of 
insulin (u/kg)
0.59 ± 0.04 0.62 ± 0.06 0.50 ± 0.11 .33
Time since transplant 
(months)
15.7 ± 2.3 16.2 ± 3.1 14.1 ± 3.1 .73
Number of transplants 2.1 ± 0.1 2.0 ± 0.2 2.2 ± 0.2 .52
IEQsa 12 644 
(10 858- 15 709)
12 478 
(10 858- 13 723)
17 147 
(10 752- 17 147)
.34
Duration of diabetes 
(years)
31 ± 2.3 31.0 ± 3.8 32.5 ± 1.6 .81
% Retinopathy 62 49 75 .58
% Neuropathyb 54 33 75 .21
% Microalbuminuria 31 37 25 .99
HbA1c 6.0 ± 0.1 6.0 ± 0.1 6.1 ± 0.2 .68
Beta score 7 ± 0 7 ± 0 6 ± 0 .36
BETA- 2 score 25 ± 3 25 ± 3 25 ± 3 .96
Personal	data	in	13	islet	transplant	recipients	undergoing	n	=	17	paired	OGTTs	and	MMTTs	in	study.
Data shown is mean±SEM or median(IQR). P - statistical testing between islet transplant recipients 
with OGTT120	<11.1	mmol/L	vs	OGTT120	≥11.1	mmol/L.
aIEQ represents total number of islets received following transplants.
bNeuropathy assessed clinically (autonomic and peripheral).
TABLE  1 Personal data of subjects
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specificity was also derived from the ROC curve analyses. In post 
hoc analyses, ROC curves of the MMTT data were constructed 
using a DI <1 and the specificity and sensitivity of the 90- minute 
MMTT- glycaemic thresholds generated in the primary analysis 
were derived.
Statistical significance was set at 5%.
3  | RESULTS
Seventeen paired OGTTs and MMTTs were performed in 13 par-
ticipants; 9 participants received one OGTT and one MMTT; four 
participants received two OGTTs and MMTTs ((mean ± SEM) 
6 ± 1 months between each paired study).
The time interval between first transplant and the metabolic test 
was (mean ± SEM) 15 ± 2 months. The paired MMTTs and OGTTs 
were performed a median (IQR) of 2(1–2) days apart.
The personal data of the subjects is shown (Table 1). Subjects 
received an average of 2.1 ± 0.1 transplants, with a mean time be-
tween the first and second transplant of 2.1 ± 0.5 months. Mean 
creatinine of subjects was 80 ± 3 μmol/L,	mean	HbA1c	6.0	±	0.1%,	
beta scores 7.0 ± 0 and BETA- 2 scores 25 ± 3 consistent with very 
good graft function.
The basal and stimulated glucose values pre and post the 
75 g OGTT and the MMTT at 120 minutes and 90 minutes re-
spectively are shown (Figure 1A, B). Five studies had OGTT120 
≥11.1	mmol/L.	 By	 WHO	 criteria,	 the	 remaining	 studies	 were	
classified	 as	 normal	 glucose	 tolerance	 (NGT)	 (n	=	5);	 isolated	
impaired	glucose	tolerance	 (IGT)	 (n	=	2);	 isolated	IFG	(n	=	1);	or	
both	 IFG	plus	 IGT	 (n	=	4).	Of	note	only	2	of	 the	5	studies	with	
OGTT120	 ≥11.1	mmol/L ,	 had	 an	 HbA1c	≥	6.5%	 (48	mmol/mol)	
or	 fasting	glucose	≥7.0	mol/L.	There	was	a	positive	correlation	
between the stimulated glucose values following the OGTT 
and the MMTT but this failed to reach statistical significance 
(r =	+.45;	P	=	.07).
Basal and stimulated C- peptide concentrations after OGTT and 
MMTT are presented in Tables 2, 3 and 4. The increment in C- peptide 
was greater after OGTT vs MMTT (P < .01; Table 4). However, the 
change in C- peptide in relation to the glucose concentrations, did 
not differ as evidenced by the AUC C- peptide in relation to the glu-
cose concentrations (Table 4).
When comparing studies with and without OGTT120 
≥11.1 mmol/L	 there	was	 no	 difference	 in	 HbA1c,	 beta	 or	 BETA-	2	
scores between the subgroups (Table 2). Subgroup analyses of the 
four participants that were examined on two separate occasions did 
not demonstrate graft deterioration over time (BETA- 2 scores and 
glucose and C- peptide concentrations during OGTT; all P > .05). Of 
the	 n	=	4	 participants	 tested	 on	 two	 occasions,	 one	 had	OGTT120 
≥11.1 mmol/L	on	both	occasions.
During the OGTTs, studies with OGTT120	≥11.1 mmol/L	vs	those	
<11.1	mmol/L	 had	 greater	 fasting	 and	 2-	hour	 glucose	 concentra-
tions, greater glucose area under the curves (AUCs) and were rela-
tively insulinopaenic with diminished 120- minute C- peptide: glucose 
concentrations, insulin: glucose and C- peptide: glucose AUC ratios 
F IGURE  1 Glucose tolerance 
and metabolic profiles post- islet 
transplantation. A, Glucose concentrations 
at 0 and 120 min post 75 g OGTT in 
studies with OGTT120	<11.1	mmol/L	(n	=	12)	vs	OGTT120	≥11.1	mmol/L	(n	=	5).	
B, Glucose concentrations at 0 and 90 min 
post MMTT in studies with OGTT120 <11.1	mmol/L	(n	=	12)	vs	OGTT120 ≥11.1	mmol/L	(n	=	5).	C,	Glucose.	D,	
C- peptide and E, Insulin concentrations 
during	a	75	g	OGTT	in	n	=	17	studies	
post islet transplantation. Open circles 
(OGTT120	<11.1	mmol/L)	vs	filled	squares	
(OGTT120	≥11.1	mmol/L)
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from 0- 120 minutes (Table 2). There was no significant difference in 
insulin sensitivity (HOMA- IR and Matsuda index). However insulin 
secretion (insulinogenic indices) and DIs were lower in the studies 
with OGTT120	≥11.1 mmol/L	(Table	2).
In contrast to the OGTT, there were no significant differences 
in the fasting and 90- minute glucose and C- peptide concentrations 
or in the 90- minute C- peptide: glucose concentrations; AUCs for 
glucose and C- peptide between 0- 90- minutes; and the C- peptide: 
All OGTT
120
 <11.1 OGTT
120
 ≥11.1 P
Tests (n) 17 12 5 - 
Fasting glucose 
(mmol/L)
6.1 ± 0.1 5.7 ± 0.1 6.8 ± 0.2 .002
120- min glucose 
(mmol/L)
9.7 ± 0.7 8.2 ± 0.6 13.4 ± 0.5 .0001
Glucose (AUC 
0- 120 min) 
mmol/L.min
1116 (934- 1313) 1023 (923- 1162) 1368 (1240- 1516) .002
Fasting 
C- peptide 
(nmol/L)
0.67 (0.58- 0.83) 0.69 (0.50- 0.80) 0.65 (0.58- 0.76) .74
120- min 
C- peptide 
(nmol/L)
2.08 (1.62- 2.38) 2.16 (2.02- 2.38) 1.50 (1.36- 2.17) .29
C- peptide (AUC 
0- 120 min)
205 (170- 212) 207 (197- 212) 185 (170- 230) .94
Fasting 
C- peptide: 
glucose
0.10 (0.08- 0.14) 0.11 (0.08- 0.14) 0.10 (0.09- 0.10) .90
120- min 
C- peptide: 
glucose
0.20 (0.12- 0.26) 0.24 (0.2- 0.35) 0.15 (0.12- 0.16) .04
C- peptide: 
Glucose (AUC 
0- 120 min)
0.17 (0.14- 0.22) 0.21 (0.18- 0.25) 0.14 (0.13- 0.15) .01
Fasting insulin 
(mU/L)
8.5 (5.5- 16.7) 9.9 (5.6- 21.9) 8.5 (5.3- 13.9) .67
120- min insulin 
(mU/L)
34.2 (29.3- 45.4) 34.1 (30.7- 44.7) 35.7 (25.3- 55.0) .90
Insulin (AUC 
0- 120 min) 
mU/L.min
2949 (2543- 5177) 3827 (2711- 5868) 2597 (2255- 3231) .12
Insulin: Glucose 
(AUC 
0- 120 min)
2.9 (1.9- 4.5) 3.9 (2.6- 5.4) 1.9 (1.8- 2.0) .02
HOMA- IR 1.7 ± 0.19 1.5 ± 0.19 2.0 ± 0.48 .31
Matsuda Index 5.1 ± 0.6 5.3 ± 1.0 4.8 ± 0.6 .70
Insulinogenic 
index
0.40 ± 0.06 0.43 ± 0.06 0.14 ± 0.01 .004
DI 1.0 (0.7- 2.0) 1.66 (1.01- 3.45) 0.65 (0.46- 0.72) .005
Metabolic	indices	from	OGTT	(n	=	17	tests)	in	all	studies	and	according	to	OGTT120 <11.1 vs OGTT120 ≥11.1.
Data shown is mean±SEM or median(IQR). DI, disposition index; FPG, fasting plasma glucose, 
HOMA- IR, homeostatic modelling assessment- insulin resistance (C- peptide).
Matsuda index, measure of insulin sensitivity; insulinogenic index, measure of insulin secretion22; DI, 
product of Matsuda index and insulinogenic index, <1 denotes relative insulin secretory defect.25 
See Appendix S1. Supplemental results show indices calculated at 90 minute time point and AUC 
0- 90 minute.
P - statistical testing between OGTT120	<11.1	mmol/L	vs	OGTT120	≥11.1	mmol/L.
TABLE  2 Metabolic data associated 
with 75 g OGTT
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glucose ratio from 0- 90- minutes during the MMTT between studies 
in those with or without OGTT120	≥11.1 mmol/L	(Table	3).
Individual glucose, C- peptide and insulin concentrations during 
the OGTT for each study are shown (Figure 1C- E). The 120- minute 
glucose and C- peptide concentrations following the 75 g- OGTT 
were significantly greater than the 90- minute MMTT glucose and 
C- peptide concentrations (Figure 2A, B) although there was no 
difference in the stimulated C- peptide: glucose ratios (Figure 2C). 
Integrated AUCs (0- 90- minutes) for glucose and C- peptide were sig-
nificantly greater following OGTTs vs the MMTTs (P < .001; Table 4).
When the analyses were repeated without the second observa-
tions in the 4 subjects, all results remained statistically significant.
The MMTT AUROC curves constructed with the 90- minute 
MMTT glucose according to OGTT120	 ≥11.1	mmol/L	was	73	±	13%.	
A	90-	minute	MMTT	glucose	 concentration	of	≥8.0	mmol/L	demon-
strated 80% sensitivity and 83% specificity for OGTT120	≥11.1	mmol/L.	
In	post	hoc	analyses	a	90-	minute	MMTT	glucose	≥	8.0	mmol/L	was	
tested in diagnosing a DI <1, which in a priori analyses had been 
demonstrated to be significantly different in subjects with OGTT120 
≥11.1	mmol/L	vs	OGTT120	<11.1	mmol/L.	Using	the	90-	minute	MMTT	
glucose	≥8.0	mmol/L	the	AUROC	for	diagnosing	a	DI	<	1	was	77%.
4  | DISCUSSION
This study in insulin- independent islet transplant recipients with sta-
ble graft function and normal renal function, examined metabolic 
All OGTT
120
 <11.1 OGTT
120
 ≥11.1 P
N tests 17 12 5
Fasting glucose 
(mmol/L)
6.4 ± 0.2 6.3 ± 0.2 6.6 ± 0.3 .38
90- min glucose 
(mmol/L)
7.8 ± 0.6 7.2 ± 0.7 9.0 ± 0.9 .16
Glucose (AUC 
0-	90	min)	mmol/L.
min
617 (542- 745) 594 (578- 626) 711 (648- 779) .17
Fasting C- peptide 
(nmol/L)
0.72 (0.56- 0.92) 0.65 (0.51- 0.89) 0.81 (0.72- 1.03) .17
90- min C- peptide 
(nmol/L)
1.40 (1.0- 1.9) 1.33 (1.01- 1.58) 1.50 (1.14- 2.25) .65
C- peptide (AUC 
0-	90	min)	nmol/L.
min
97 (81- 129) 91 (80- 105) 99 (86- 166) .27
Fasting C- peptide: 
glucose
0.11 (0.10- 0.14) 0.10 (0.08- 0.15) 0.13 (0.11- 0.14) .33
90- min C- peptide: 
glucose
0.21 (0.16- 0.25) 0.22 (0.16- 0.28) 0.17 (0.16- 0.21) .32
C- peptide: Glucose 
(AUC 0- 90 min)
0.16 (0.13- 0.20) 0.17 (0.12- 0.23) 0.15 (0.13- 0.18) .79
Metabolic	Indices	from	MMTT	(n	=	17	tests)	in	all	studies	and	according	to	OGTT120	<11.1	mmol/L	
vs OGTT120	≥11.1	mmol/L.	Data	shown	is	mean±SEM	or	median(IQR).
P - statistical testing between OGTT120	<11.1	mmol/L	vs	OGTT120	≥11.1	mmol/L.
TABLE  3 Metabolic data associated 
with MMTT
TABLE  4 Metabolic data associated with 75 g- OGTT vs. MMTT
OGTT MMTT P
Tests (n) 17 17 - 
FPG	(mmol/L) 6.1 ± 0.1 6.4 ± 0.2 .07
Stimulated 
glucose	(mmol/L)
9.7 ± 0.7 7.8 ± 0.6 .01
Glucose (AUC) 
(mmol/L	min)
1116 (934- 1313) 617 (542- 745) <.001
Fasting C- peptide 
(nmol/L)
0.67 (0.58- 0.83) 0.72 (0.56- 0.92) .12
Stimulated 
C- peptide 
(nmol/L)
2.08 (1.62- 2.38) 1.40 (1.0- 1.9) .002
C- peptide (AUC) 
(nmol/L	min)
205 (166-215) 97 (81-119) <.001
Fasting C- peptide: 
glucose
0.10 (0.08- 0.14) 0.11 (0.10- 0.14) .08
Stimulated 
C- peptide: 
glucose
0.20 (0.12- 0.26) 0.21 (0.16- 0.25) .33
C- peptide: glucose 
(AUC)
0.17 (0.14- 0.22) 0.16 (0.13- 0.23) .85
Metabolic Indices from OGTT vs. MMTT in all participants.
Stimulated glucose and C- peptide measured at 120- min post- OGTT; 90- 
min post- MMTT.
AUC glucose and C- peptide measured between 0- to 120- min post- 
OGTT and from 0- to 90- min post- MMTT.
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responses to a standardized oral glucose challenge and a mixed meal 
challenge. Not surprisingly there was a much greater increment in 
glucose after the larger glucose load of the OGTT, but both tests 
provided an equivalent estimate of graft function as judged by the 
integrated C- peptide in relation to the circulating glucose concentra-
tions. Furthermore, we have shown that a 90- minute MMTT glucose 
≥8.0	mmol/L	is	equivalent	to	a	2	hour	glucose	≥11.1	mmol/L	after	a	
standard 75 g- OGTT. Of note no participants were on exogenous 
insulin or oral hypoglycaemics and therefore there was no confound-
ing of metabolic results. Even in this highly selected cohort of nar-
row segment of subjects with insulin- independent islet transplant 
recipients with very good graft function (shown by beta and BETA- 2 
scores), stimulation tests can identify individuals with sub- optimal 
graft function whose grafts may benefit from some metabolic 
support.
The MMTT is a valuable tool used to quantify graft function, 
rather than to identify glucose intolerance. Nevertheless, post- 
challenge glucose concentrations were significantly higher after 
OGTT than post- MMTT which is consistent with the MMTT being a 
more physiological and less potent stimulus of insulin secretion and 
therefore a less stringent challenge to graft function. While the post- 
MMTT glucose levels were not able to reliably discriminate between 
those with and without OGTT120	 ≥11.1	mmol/L,	 both	 OGTT	 and	
MMTT were useful stimuli for insulin secretion measured by AUC 
for insulin and C- peptide. Such physiological testing with a standard-
ized MMTT which contains less than half the amount of carbohy-
drate compared to a 75 g- OGTT, avoids unnecessary hyperglycemia 
therefore exposing the islet graft to less metabolic stress, is the pre-
ferred option to assess graft function following islet transplantation 
and is widely adopted by islet transplantation programmes world- 
wide permitting comparisons between subjects or within subjects 
over time.4,27 Furthermore, such physiological testing has been ad-
opted in new onset diabetes trials including TrialNet.19 A liquid meal 
is not truly physiologic however, and is associated with more rapid 
delivery of nutrients to the duodenum than after a solid meal.33 It 
does however avoid the confounding of delayed gastric emptying 
which might be anticipated in a cohort with long diabetes duration 
and high prevalence of diabetic neuropathy.
Raised fasting and post- prandial glucose are secondary to defects 
in either insulin secretion, insulin sensitivity, or both.34 The abnormal 
insulinogenic index and DI is consistent with defects in insulin secre-
tion in these subjects with OGTT120	≥11.1	mmol/L	post-	islet	trans-
plantation.	Loss	of	the	first	phase	insulin	response	with	diminished	
suppression of hepatic glucose production, may be associated with 
fasting	glucose	concentrations	as	low	as	5.0-	5.4	mmol/L,35 and are 
well described in islet transplant recipients 10,36 concordant with our 
observations where a high prevalence of impaired fasting glucose 
was seen. The mechanism is not known but diminished pulsatility of 
insulin secretion may play a role.37-42 Such studies underline the im-
portance of studying islet transplant participants distinct from other 
groups with diabetes and extrapolations of data from other subjects 
with diabetes including those who are C- peptide positive, may be 
inappropriate.43,44
Of note the subjects selected for islet transplantation were 
insulin sensitive with normal body mass index (BMI).6 As insulin 
sensitivity was not measured by gold standard hyperinusulinaemic 
euglycaemic clamp studies, subtle defects in insulin sensitivity may 
have been missed. Certainly, immunosuppression with tacrolimus is 
recognized to induce insulin resistance and may contribute to insulin 
secretory deficits in some subjects; how this relates to the dose of 
immunosuppression as well as to their concentration is incompletely 
understood.45-47 In this study, subjects were receiving sirolimus and 
F IGURE  2 Stimulated glucose (A), stimulated C- peptide (B) and stimulated C- peptide: glucose concentrations (C) following 75 g- OGTT 
and MMTTs in islet transplant recipients. Glucose (A), stimulated C- peptide (B) and C- peptide: glucose concentrations (C) at 120- min 
following	a	75	g	OGTT	and	corresponding	metabolite	concentrations	at	90-	min	post	MMTT	in	n	=	17	studies	post	islet	transplantation.	
Open circles (OGTT120	<11.1	mmol/L)	vs	filled	squares	(OGTT120	≥11.1	mmol/L).	Dashed	lines	-	median	values	for	subjects	in	tests.	Note	
paired metabolites compared at 90 min post OGTT vs MMTT: glucose concentrations (P =	.004),	stimulated	C-	peptide	(P	=	.003),	stimulated	
C- peptide: glucose (P	=	.60)
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lower	 doses	 of	 tacrolimus	 (trough	 target	 4-	6	ng/mL)	 than	 is	 com-
monly employed when tacrolimus is combined with mycophenolate 
mofetil.
Studies that have examined subjects with Type 1 diabetes with 
paired OGTT and MMTTs have also demonstrated a 30% lower glu-
cose concentrations with the latter test.48 Other studies comparing 
the standardized MMTT to a 75 g- OGTT in subjects with a range 
of glucose tolerance who had repeated tests, demonstrated a lin-
ear correlation between the two tests at 120 minutes.49 This result 
concords with our observation of a positive association between the 
stimulated glucose values following the MMTT and the 75 g OGTT, 
although in our study this just failed to meet statistical significance. 
The MMTT has been shown to be associated with lower glucose 
variability, fewer adverse symptoms and greater palatability vs the 
OGTT.49
The primary analyses revealed a close relationship between 
the	 MMTT	 90-	minute	 glucose	 ≥8.0	mmol/L	 and	 glucose	 intol-
erance indicated by OGTT120	 ≥11.1	mmol/L.	 As	 the	 objective	
of metabolic testing is to assess graft function post hoc analy-
ses were also performed to explore insulin secretion using ROC 
curves constructed using the DI < 1, a composite score reflecting 
defective insulin secretion in relation to the insulin sensitivity.30,50 
Such analyses confirmed the close association of the 90- minute 
MMTT glucose with this further measure of graft dysfunction. Of 
note the HbA1c did not differ between islet transplant recipients 
with OGTT120	≥11.1	mmol/L	vs	those	<11.1	mmol/L	and	therefore	
HbA1c was not examined further in secondary analyses. It is pos-
sible that recent onset of dysglycaemia could explain the similar 
HbA1c levels in subjects with and without diabetes, but more 
likely reflects the relatively low sensitivity of HbA1c for diagnosis 
of diabetes.
Of note variability in fasting plasma glucose on the days of 
the tests was observed. This did not reach statistical significance 
but intra- individual glycaemic variability in approximately 15% is 
well recognized even under standardized conditions as reported 
here.51
As a diagnosis of diabetes reflects inadequate insulin secretion 
to maintain euglycaemia these studies are important as they help 
identify a threshold where islet graft function may be sub- optimal. 
Although the MMTT does not clearly differentiate those with and 
without OGTT120	 ≥11.1	mmol/L,	 it	 does	 identify	 a	 corresponding	
threshold	(90-	minute	glucose	≥	8	mmol/L)	associated	with	reduced	
DI. This threshold may identify subjects whose graft function should 
be monitored more closely; prompt efforts to minimize metabolic 
demands (perhaps through changes to nutrition and physical activ-
ity), or suggest consideration of therapies to support the graft or 
lower blood glucose levels (e.g. supplementary exogenous insulin, 
or other anti- hyperglycemic agents). Delaying the institution of anti- 
hyperglycemic therapies until overt hyperglycemia, late in the spec-
trum of declining beta- cell function, will have limited ability to alter 
the natural history of beta- cell failure.
A limitation of the study is that glucose concentrations post- 
MMTT were only measured at 90 minutes and not at 120 minutes or 
indeed earlier time points including 30 and 60 minutes. As the peak 
glucose during a MMTT may occur at 30 or 60 minutes, using only 
a 0 to 90 minute may not accurately reflect the ‘true’ AUC, and may 
be an unfair comparison, side- by- side, to the OGTT AUC which has 
more values for calculation. Our comparisons of glycaemic indices 
with both tests at 90 minutes however concord with the literature49 
but comparisons of the MMTT and OGTT data at 120 minutes post- 
stimulus is not possible with our data set. However, as most units 
perform glucose concentrations 90- minutes post- MMTT in islet 
transplant recipients, these results are of clinical utility. A further 
limitation of the study is the relatively small numbers of subjects 
studied. However, there are no other published studies comparing 
MMTTs and OGTTs in islet transplant recipients, and this study of-
fers new insights in the field.
In summary we have studied a cohort of insulin- independent 
subjects that have undergone islet transplantation for Type 1 di-
abetes with stable graft function and demonstrate a close associ-
ation	between	 a	MMTT	90-	minute	 glucose	≥8.0	mmol/L	 and	 the	
120 minute OGTT threshold for the diagnosis of diabetes (OGTT120 
≥11.1	mmol/L).22 These studies reflect glycaemic thresholds during 
a MMTT that may identify individuals appropriate for intervention 
and intensification of efforts to support and protect graft function 
in the context of islet transplantation. Further studies are required 
to determine if early interventions alters the attrition in graft func-
tion seen post- transplantation and whether this in turn enhances 
the long- term benefits of islet transplantation to maintain good gly-
caemic control and protection from severe hypoglycemia.
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